CX-2029, a PROBODY drug conjugate targeting CD71 (transferrin receptor): Results from a first-in-human study (PROCLAIM-CX-2029) in patients (Pts) with advanced cancer.

Melissa L. Johnson, Alexander I. Spira, Navid Hafez et al.|Journal of Clinical Oncology|2020

Cited by 18